Dr Weber on the Prognostic Utility of ctDNA Dynamics in Melanoma
Source: OncLive, November 2023
Jeffrey S. Weber, MD, PhD, discusses the use of circulating-tumor DNA dynamics when guiding treatment decision-making in melanoma, according to data from the phase 2b mRNA-4157-P201/KEYNOTE-942 trial.
Jeffrey S. Weber, MD, PhD, deputy director, codirector, the Melanoma Research Program, NYU Langone Perlmutter Cancer Center, Laura and Isaac Perlmutter Professor of Oncology, NYU Grossman School of Medicine, discusses the use of circulating-tumor DNA (ctDNA) dynamics when guiding treatment decision-making in melanoma, according to data from the phase 2b mRNA-4157-P201/KEYNOTE-942 trial (NCT03897881).
This randomized study compared the personalized mRNA-based neoantigen therapy mRNA-4157 (V940) in combination with pembrolizumab (Keytruda) vs pembrolizumab alone in patients with resected, high-risk melanoma.